newsfilter
← Latest News
ACCESS Newswire·

Medicus Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update

  • Medicus Pharma Ltd. reported Q3 2026 financial results with $13.1 million in total cash, cash equivalents, and restricted cash, including $5.0 million in cash and cash equivalents.
  • The Company designated CD228V as its principal development priority following a September 2, 2026, co-development and license agreement with Pfizer Inc. for the antibody-drug conjugate.
  • Pfizer provided $2.0 million in initial development funding for CD228V, which targets melanotransferrin (CD228) with an initial focus on melanoma proof-of-concept.
  • Medicus announced a non-binding Letter of Intent on November 4, 2026, for a proposed SPAC business combination involving SkinJect® at an approximate $135 million pre-money valuation.
  • SkinJect® will focus exclusively on Gorlin syndrome treatment, with an upcoming SKNJCT-005 Phase 2b study authorized by the FDA to support a potential New Drug Application.
  • The Company submitted an optimized Teverelix® registrational protocol to the FDA for advanced prostate cancer in patients with increased cardiovascular risk, seeking a strategic partner rather than independent funding.
  • Medicus regained compliance with Nasdaq's minimum bid price requirement following a 50-to-1 share consolidation effective October 12, 2026.
  • The Company terminated its standby equity purchase agreement with Yorkville on September 11, 2026, with no outstanding borrowings or shares.
  • Q3 2026 net loss was $15.2 million, or $11.64 per share (retroactively adjusted for share consolidation), compared to a $16.0 million loss in Q3 2025.
  • Management plans to maintain a capital-efficient strategy by supporting SkinJect® \& Teverelix® as partner-ready programs while focusing resources on CD228V milestones.
Company
Medicus Pharma Ltd
Keywords
Healthcare & Pharmaceutical, Earnings